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Abstract 
The Musashi family of mRNA translational regulators 
control both physiological and pathological stem cell self-
renewal primarily by repressing target mRNAs that promote 
differentiation.  In response to differentiation cues, Musashi 
can switch from a repressor to an activator of target mRNA 
translation.  However, the molecular events that distinguish 
Musashi-mediated translational activation from repression 
are not understood.  We have previously reported that 
Musashi function is required for the maturation of Xenopus 
oocytes, and specifically for translational activation of 
specific dormant maternal mRNAs.  Here, we employed 
mass spectrometry to identify cellular factors necessary for 
Musashi-dependent mRNA translational activation.  We 
report that Musashi1 needs to associate with the embryonic 
poly(A) binding protein (ePABP) or the canonical somatic 
cell poly(A) binding protein PABPC1 for activation of 
Musashi target mRNA translation.  Co-
immunoprecipitation studies demonstrated an increased 
Musashi1 interaction with ePABP during oocyte 
maturation.  Attenuation of endogenous ePABP activity 
severely compromised Musashi function, preventing 
downstream signaling and blocking oocyte maturation.  
Ectopic expression of either ePABP or PABPC1 restored 
Musashi-dependent mRNA translational activation and 
maturation of ePABP attenuated oocytes.  Consistent with 
these Xenopus findings, PABPC1 remained associated with 
Musashi under conditions of Musashi target mRNA de-
repression and translation during mammalian stem cell 
differentiation.  Since association of Musashi1 with poly(A) 
binding proteins has previously been implicated only in 
repression of Musashi target mRNAs, our findings reveal 
novel context-dependent roles for the interaction of 
Musashi with poly[A] binding protein family members in 
response to extracellular cues that control cell fate.  
_____________________________________________ 
 
The Musashi family of translational control proteins 
(Musashi1 and Musashi2) interact in a sequence-specific 
manner with target mRNAs and have been shown to be 
markers of stem and progenitor cell populations in 
mammalian tissues, where Musashi acts to promote stem 
cell self-renewal and oppose cell differentiation (1-10).  
Recent evidence suggests that Musashi may also play a role 
in controlling plasticity of more differentiated cells (11,12).  
Consistent with the physiological control of stem cell 
maintenance, Musashi1 and Musashi2 have also been 
implicated pathologically in the promotion of cancer stem 
cell self-renewal and disease progression (13-24). 
 
The Musashi proteins were originally identified as 
repressors of target mRNA translation (1,8,25,26). The 
mechanism of repression has been proposed to involve 
Musashi1 interaction with PABPC1, the predominant 
cytoplasmic poly(A) binding protein (27).  Musashi1 was 
shown to compete with the eIF4G translational initiation 
factor for the same interaction site within the first two RNA 
recognition motifs (RRMs) of PABPC1.  As a consequence 
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of this competition, it was suggested that the 
Musashi1:PABPC1 interaction prevented recruitment of the 
large 60S ribosomal subunit and subsequent cap-dependent 
translation of Musashi1 target mRNAs (27).   
 
Our group was the first to report a critical role for Musashi 
in promoting activation, rather than repression, of target 
mRNA translation (28-30).  During the transition of oocytes 
to fertilizable eggs in the frog, Xenopus laevis, gene 
transcription is suppressed and all new proteins necessary 
for oocyte maturation are translated from pre-existing 
maternal mRNAs (31,32).  Translational activation of these 
dormant mRNAs involves release of repression and occurs 
in a sequential manner specified by three evolutionarily 
conserved mRNA sequence-specific translational 
regulators: Pumilio; Musashi; and the cytoplasmic 
polyadenylation element binding (CPEB1) (33,34).  In 
response to progesterone-triggered maturation of immature 
oocytes, a signal transduction pathway initiates de-
repression of the Pumilio target mRNA, Ringo (35).  Newly 
synthesized Ringo protein stimulates cyclin-dependent 
kinase (CDK) activity (36-38) which, in turn, initiates 
phosphorylation of Musashi and translational activation of 
Musashi target mRNAs, such as the mRNA encoding the 
MAP kinase kinase kinase, Mos (39).  Translation of Mos 
and subsequent activation of MAP kinase signaling 
mediates a positive feedback amplification loop that drives 
robust Musashi activation, as well as activation of CPEB-
dependent late class mRNA translation and the all-or-none 
transition to commit to complete oocyte maturation 
(29,30,34). 
 
Musashi-dependent mRNA translational activation has 
subsequently been reported in multiple mammalian systems 
(for example (6,24,40-42)).  The Musashi proteins are thus 
bifunctional and can switch from mediating repression to 
promoting activation of target mRNAs in response to 
appropriate extracellular stimuli (6,39,43,44).  We have 
demonstrated that the switch in Musashi function is 
dependent upon the phosphorylation of two conserved 
serine residues in the C-terminal of the protein (39,43,44).  
The exact mechanism by which phosphorylation facilitates 
de-repression and promotes Musashi’s ability to drive 
translation is unclear, but may involve altered interaction 
with, or altered function of, critical co-factors including 
PABPC1 (27), the microRNA-binding protein Lin28 which 
modulates let-7 miRNA biogenesis (45), or the poly(A) 
polymerase Germline Development 2 (GLD2) (46).   
 
In this study, we employed mass spectrometry to identify 
Musashi-specific interacting proteins that are required for 
Musashi-dependent translational control.  We report 
identification and characterization of several members of 
the poly(A) binding protein family, namely the embryonic 
poly(A) binding protein (ePABP), which is functionally 
required for oocyte maturation and is the most abundant 
poly(A) binding protein in immature oocytes (47,48); 
PABP4, a newly identified member of the poly(A) binding 
protein family that contributes uniquely to aspects of early 
Xenopus embryo development (49); and PABPC1, although 
PABPC1 interaction was restricted to maturing oocytes.    
Contrary to the model in which interaction with poly(A) 
binding protein mediates repression of Musashi target 
mRNAs, we report that interaction with either ePABP or 
PABPC1 is necessary to promote Musashi target mRNA 
translational activation.  Interestingly, we observed that 
Musashi is also associated with PABPC1 in a mammalian 
cancer cell line and in human stem cells under conditions of 
Musashi target mRNA translational activation and inhibited 
stem cell self-renewal.  Together, our results indicate that 
the context-dependent interactions of Musashi with poly(A) 
binding proteins confer a differential ability to control target 
mRNA translation and cell fate. 
 
Results 
The Musashi interactome is dynamically regulated in 
response to progesterone stimulation. 
To better understand the molecular components that 
facilitate Musashi-dependent mRNA translational control, 
we sought to identify interacting partner proteins in both 
immature oocytes (where target mRNAs are repressed) and 
progesterone-stimulated oocytes (where target mRNAs are 
translationally activated).  In three separate experiments, we 
microinjected immature Xenopus oocytes with RNA 
encoding either a GST-tagged form of Musashi1 to facilitate 
recovery of co-associated proteins after partial purification 
over glutathione sepharose or the GST moiety alone.  
Oocytes were incubated overnight to allow expression of 
the ectopic proteins, and then the GST-Musashi1 injected 
oocytes or control GST-injected oocytes were each split into 
two pools, one of which was left untreated (immature) and 
the other stimulated with progesterone.  Following liquid 
chromatography-coupled tandem mass spectrometry, the 
spectral counts from identified proteins were normalized for 
protein size, giving us a Normalized Spectral Abundance 
Factor (NSAF) (50) and transformed to log2 with which to 
compare the relative abundance of each identified protein 
interacting with either GST-Musashi1 or GST 
(Supplemental Table 1).  Fifty proteins specifically 
interacted with the GST-Musashi1 protein but not the GST 
moiety alone (Figure 1A).  Of these, 40 were found to 
associate with Musashi1 in immature oocytes 
(Supplemental Table 2) while 29 associated with Musashi1 
in progesterone stimulated oocytes (Supplemental Table 3).  
A comparison of the two lists revealed that 19 proteins 
remain associated with Musashi1 under either experimental 
condition (and represent a “core” interactome), 21 proteins 
preferentially associate with Musashi1 only in immature 
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oocytes whereas 10 preferentially associate only in 
maturing oocytes (Supplemental Table 4).  These 
observations suggest that the Musashi1-mRNA 
ribonucleoprotein (mRNP) complexes undergo dynamic 
remodeling in response to progesterone stimulation when 
Musashi target mRNAs are de-repressed and transition to a 
state of translational activation.  Several known Musashi1 
interacting proteins were detected in our analyses, including 
the cytoplasmic polyadenylation element binding protein 
(CPEB1) (51) in immature oocytes and PABPC1 (27) in 
maturing oocytes.  The recovery of PABPC1 only in 
maturing oocytes likely reflects its reciprocal expression to 
ePABP, with PABPC1 being present at only low levels in 
immature oocytes and gradually increasing during 
maturation and early embryogenesis (48).    Interestingly, 
we detected Musashi1 association with two additional 
members of the poly(A) binding protein family (Figure 1A, 
the embryonic poly(A) binding protein, ePABP (also called 
PABPC1L) and PABP4 (also called inducible PABP or 
PABPC4)) in both immature and maturing oocytes.  Gene 
set enrichment analysis revealed that the 50 identified co-
associated proteins are primarily involved in RNA binding 
and translational regulation (Figure 1B).   
 
Musashi associates with the embryonic poly(A) binding 
protein (ePABP) in immature and maturing oocytes. 
The persistence of ePABP and PABP4 interactions in 
Musashi mRNP complexes in maturing oocytes and indeed 
the progesterone-dependent recruitment of PABPC1 was 
unexpected since Musashi target mRNAs are translationally 
activated, not repressed, in maturing oocytes.  Here, we 
have sought to determine the role and contribution of 
ePABP and PABPC1 to Musashi-dependent mRNA 
translational activation and oocyte maturation.   
 
To confirm the interaction of ePABP with Musashi1 seen 
by mass spectrometry, immature oocytes were injected with 
RNA encoding GST-tagged Xenopus Musashi1 or the GST 
moiety alone and the ability of Musashi1 to associate 
specifically with endogenous ePABP was determined after 
partial purification over glutathione sepharose and western 
blotting.  To ensure that any associations observed were due 
to protein:protein interactions rather than just co-occupancy 
of the same mRNA, all glutathione pulldown experiments 
included an RNase1 treatment step.  Endogenous ePABP 
was found to co-associate in an RNA-independent manner 
with Musashi1 in both immature and progesterone-treated 
oocytes (Figure 2A).  When compared to levels of ePABP 
in the input lysates, less than 2% of the cellular ePABP was 
found in association with Musashi1.  No co-association was 
observed with the GST moiety alone, indicating a specific 
interaction between Musashi1 and ePABP, verifying our 
mass spectrometry findings.  Quantitation of ePABP 
recovery (normalized for the amount of GST-Musashi1 in 
each pulldown) revealed a 2-fold increase in ePABP 
association with Musashi1 after progesterone stimulation 
(Figure 2B).  This increase was observed in progesterone-
stimulated oocytes that had not yet completed germinal 
vesicle (nuclear) breakdown (GVBD (-)), as well as oocytes 
which had completed GVBD (+).  We conclude that 
increased association of ePABP with Musashi1 is an early 
event during progesterone-stimulated oocyte maturation, 
occurring prior to GVBD.   
 
Knockdown of ePABP attenuates Musashi-dependent 
MAP kinase signaling and blocks oocyte maturation. 
While it has been proposed that Musashi interaction with 
PABPC1 correlated with target mRNA repression in a 
mammalian cell line (27), Musashi has a unique role during 
the maturation of Xenopus oocytes where it mediates the 
translational activation of early class mRNAs prior to 
oocyte GVBD (29,30,44,52,53).  We therefore 
hypothesized that the interaction of ePABP with Musashi1 
may be necessary to promote Musashi target mRNA 
translation during oocyte maturation.  To directly assess the 
functional role and interdependence of the 
Musashi1:ePABP interaction, we first injected immature 
oocytes with Musashi1 and Musashi2 antisense 
oligonucleotides (Msi AS) which abolish progesterone-
dependent maturation (29,39,44) and then sought to rescue 
the deficit with either ectopic Musashi1 or ePABP 
expression.  While ectopic Musashi1 was able to efficiently 
rescue maturation, ePABP expression was unable to effect 
any rescue, even at later time points (Figure 3A).  In a 
reciprocal experiment, immature oocytes were injected with 
antisense oligonucleotides that block ePABP translation 
(49) and the consequences on progesterone-stimulated 
maturation assessed.  Microinjection of the ePABP 
antisense oligonucleotides ablated progesterone-stimulated 
maturation(Figure 3B), a phenotype indistinguishable from 
Musashi antisense oligonucleotide injection (Figure 3A).  
The block to maturation appeared to be specific, as it could 
be efficiently rescued by injection of ePABP mRNA 
containing nucleotide wobble (49) to prevent antisense 
targeting but maintain correct ePABP amino acid sequence 
integrity (Figure 3B) with >90% rescue observed at later 
time points.  By contrast, ectopic expression of Musashi1 
was unable to effect any rescue of ePABP AS injected 
oocytes.  Taken together, these results suggest an 
interdependence of Musashi1 and ePABP for progesterone-
stimulated oocyte maturation.   
 
Using protein lysates prepared from oocytes shown in 
Figure 3B, the disruption of the oocyte maturation signaling 
cascade following ePABP antisense injection was analyzed 
by western blotting (Figure 3C).  While having little effect 
on the basal levels of ePABP in immature oocytes, ePABP 
antisense oligonucleotides completely prevented the 
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progesterone-stimulated increase in ePABP levels in 
maturing oocytes (Figure 3C, upper panel).  As a control for 
specificity, scrambled antisense oligonucleotides did not 
prevent the ePABP increase after progesterone stimulation.  
Ringo, an atypical CDK partner that is required for initial 
Musashi1 phosphorylation and activation (39), was 
translated normally despite ePABP antisense injection 
(Figure 3C, Ringo).  Consistent with Ringo protein 
translation and CDK activation, a low level of initial 
Musashi1 activating phosphorylation was observed in 
ePABP antisense-injected oocytes (Figure 3C, pMsi1).  
However, the robust phosphorylation of Musashi1 seen in 
control (scrambled antisense injected) oocytes was blocked 
by ePABP antisense injection.  Furthermore, downstream 
MAP kinase activation (Figure 3C, pMAPK) was severely 
attenuated after ePABP antisense injection, suggesting a 
block of early class Mos mRNA translation, the primary 
activator of MAP kinase signaling in the oocyte and a 
known Musashi1 target mRNA.  We thus position the effect 
of the ePABP antisense oligonucleotide block as acting 
immediately downstream of initial Musashi1 activation 
(Figure 3D). 
 
The observed signaling defects in ePABP antisense injected 
oocytes suggested that ePABP is required during Musashi-
directed early class mRNA translation, particularly for the 
early Mos mRNA.  To test this hypothesis directly, we 
analyzed the polyadenylation status of the Mos and Nrp1b 
(which encodes Xenopus Musashi1) mRNAs, two 
established Musashi targets (28,30,53). Treatment with 
ePABP antisense attenuated progesterone-stimulated 
polyadenylation of both mRNAs compared to control 
oocytes (Figure 4A-C, indicated by reduced PCR product 
size).  This finding indicated that ePABP plays a role in 
polyadenylation of Musashi-dependent mRNAs, possibly 
through protection of the newly added poly(A) tail or 
modulation of the rate of poly(A) addition.  We note that the 
extent of inhibition of polyadenylation was not as great as 
that seen in Musashi antisense oligonucleotide-injected 
oocytes.  We have previously demonstrated that late class, 
CPE-dependent mRNA translational activation occurs at 
GVBD and requires prior activation of Musashi-dependent 
mRNA translation (29,30,52,53).  The fact that we do not 
see CPE-dependent cyclin A1 polyadenylation in either 
Musashi or ePABP antisense injected oocytes (Figure 4A 
and D) can thus be explained by the oocytes failing to 
properly engage the early class (Musashi-dependent) 
mRNA activation that is required to allow subsequent 
activation of late class mRNAs and progression to GVBD 
(54,55).  Taken together, our results indicate that ePABP is 
necessary for robust Musashi-dependent mRNA 
polyadenylation and translational activation. 
 
Deletion mapping reveals two distinct interaction sites 
for ePABP within the Musashi1 protein. 
Having established a coincident requirement for both 
ePABP and Musashi for early mRNA polyadenylation and 
translational activation, we next sought to map the 
domain(s) within Musashi1 necessary for ePABP 
interaction.  A series of Xenopus Musashi1 (XMsi1) 
deletion mutant constructs were generated and tested for 
interaction with endogenous ePABP (Figure 5A).  Two 
interaction domains were identified in Musashi1.  The first 
encompasses amino acids 190-240, the previously 
characterized domain necessary for PABPC1 interaction 
(27).  As can be seen in Figure 5C (left panel), expression 
of this domain alone (XMsi 190-240) was sufficient to 
retain significant interaction with endogenous ePABP, 
while further truncations within this region either 
dramatically attenuated ePABP interaction (XMsi1 190-230 
and 190-220) or ablated interaction completely (XMsi1 
210-240).  A second, weaker binding site was identified 
within the N-terminal of Musashi1 spanning the end of the 
first RNA recognition motif (RRM1) and the start of RRM2 
(amino acids 80–120).  A comparison of these two 
interaction domains within Musashi1 revealed no obvious 
linear amino acid sequence homology.   
 
We observed that while murine Musashi1 was also able to 
associate with ePABP to a similar degree as observed with 
Xenopus Musashi1 (Figure 5B, mMsi1 WT), both the 
Xenopus Musashi2 (Figure 7A and B) and murine Musashi2 
proteins (Figure 5C) exhibited a more than a 4-fold reduced 
interaction with ePABP.  The N-terminal 80-120 amino acid 
domain is well conserved between Xenopus Musashi1 and 
Musashi2 (95% amino acid identity), between Xenopus 
Musashi1 and murine Musashi1 (100% identity) as well as 
between Xenopus Musashi2 and murine Musashi2 (97.5% 
identity).  However, there is considerably more divergence 
in the C-terminal 190-240 domain between Xenopus 
Musashi1 and Xenopus Musashi2 (64% identity) as well as 
between murine Musashi1 and Musashi2 (64% identity).  
We propose that the reduced interaction of ePABP with 
Musashi2 when compared to Musashi1 is primarily due to 
isoform-specific sequence divergence within the C-terminal 
190-240 interaction domain.   
 
In a reciprocal set of experiments, we sought to map the 
Musashi1 binding sites within ePABP using yeast two-
hybrid analyses.  Vertebrate PABPs consist of four RRMs 
and a C-terminal region containing a variable linker region 
and a highly conserved PABC domain (Figure 6A).  As 
mammalian Musashi1 was reported to repress translation by 
binding to PABPC1 RRMs 1-2 and disrupting the 
interaction of PABPC1 with eIF4G (27), we initially 
focused on this domain.  Two RNA-binding proteins, MS2 
coat protein (MS2) and iron regulatory protein (IRP)-1 were 
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utilized as negative controls for specificity, and eIF4G 
served as a positive control.  Surprisingly, neither the N or 
C-terminal fragments of Musashi1 interacted with RRMs 1-
2 of PABPC1 or ePABP, and although full-length Musashi1 
appeared to interact, this was RNA-dependent as point 
mutations in the RNP motifs of PABPC1 RRMs 1-2 that 
disrupt RNA-binding abrogated this interaction (Figure 
6B).  In contrast, the interaction between eIF4G and the 
RNA binding mutant form of PABPC1 RRMs 1-2 was 
maintained (Figure 6B).  PABPC1 or ePABP RRMs 3-4 
also failed to interact with either the N or C-terminal regions 
of Musashi1 (data not shown).  The PABP C-terminal 
region does not bind RNA but has been characterized as a 
protein interaction domain.  We observed that both full-
length Musashi1 and the C-terminal fragment of Musashi1 
showed robust interaction with the C-terminus of both 
ePABP and PABPC1, with weaker interactions being 
observed with the N-terminal region of Musashi1 (Figure 
6C).  These yeast two hybrid mapping experiments are in 
general agreement with the GST pull-down analyses 
(Figure 5A-C).  We conclude that the C-terminal domains 
of ePABP and PABP1 interact directly with the 190-240 
domain (and to a lesser extent the 80-120 domain) of 
Musashi1.   
 
Differential ePABP interaction correlates with 
functional differences between Musashi1 and Musashi2. 
Our interaction mapping of ePABP binding sites within 
Musashi1 and Musashi2 revealed that ePABP binding to 
Musashi2 was significantly reduced compared to Musashi1 
(Figures 5, 7A and 7B).  To assess if the differential 
interaction with ePABP reflected any functional differences 
between Musashi1 and Musashi2, we assayed the ability of 
Musashi1 and Musashi2 to rescue oocytes that had been 
previously injected with Musashi antisense 
oligonucleotides.  Given sufficient time, Musashi2 was 
eventually able to rescue maturation to the same extent as 
Musashi1.  However, when assessed at the time when 
Musashi1 had effected maturation of 50% of the oocytes, 
Musashi2 was compromised in rescue ability (Figure 7C). 
This rescue deficit was a consequence of the reduced rate at 
which Musashi2 was able to mediate progesterone-
stimulated maturation since Musashi2 was expressed to 
similar levels as the Musashi1 protein (Figure 7D).  We 
reasoned that the stronger interaction of Musashi1 with 
ePABP was necessary for the rapid endogenous mRNA 
translational activation and consequently determined the 
rate of maturation.  In theory, an enhancement of ePABP 
interaction with Musashi2 would allow Musashi2 to 
function at the same rate as Musashi1 in the antisense rescue 
assay.  To test this idea we generated a chimeric Musashi2 
protein where amino acids 190-240 of Musashi2 were 
substituted with amino acids 190-240 from Musashi1, 
creating a full length Musashi2 protein encoding the 
Musashi1 ePABP interaction domain.  The resulting 
chimeric Musashi2 protein showed a robust gain of function 
in our antisense rescue assay, and was functionally 
indistinguishable from the wild-type Musashi1 protein 
(Figure 7C, Chimera).  We propose that the relative ePABP 
interaction strength may contribute to the difference 
between the functional capacities of Musashi1 and 
Musashi2 protein isoforms to exert timely translational 
activation during Xenopus oocyte maturation.  
 
Our mass spectrometry also detected interaction of 
PABPC1 with Musashi1, although this was restricted to 
maturing oocytes (Figure 1A). We thus sought to confirm 
this interaction and determine if PABPC1 also interacted 
differentially with Musashi1 and Musashi2. We co-
expressed GST-tagged Xenopus PABPC1 with either GFP-
tagged Musashi1 or Musashi2 and assessed their ability to 
co-associate in an RNA-independent manner.  Consistent 
with the ePABP interaction results, PABPC1 was found to 
preferentially interact with Musashi1, and to a lesser extent 
with Musashi2 (Figure 8A and 8B).   We next determined if 
the PABPC1 isoform could function to promote 
progesterone-dependent Musashi target mRNA translation 
and maturation of oocytes.  We expressed GST-tagged 
Xenopus PABPC1 in ePABP antisense oligonucleotide 
injected oocytes and assessed the ability of PABPC1 to 
exert rescue of progesterone-dependent maturation.  
Importantly, PABPC1 was able to efficiently rescue 
progesterone-stimulated oocyte maturation (Figure 8C) 
with >90% rescue observed at later time points.  At least in 
the context of the maturing oocyte, PABPC1 and ePABP 
appear to be functionally redundant as ectopic PABPC1 
rescued ePABP antisense-treated oocytes at the same rate 
and to the same extent as ectopically expressed ePABP.  We 
conclude that PABPC1, like ePABP, associates with 
Musashi and facilitates Musashi-dependent mRNA 
translational activation.   
 
PABPC1 is associated with Musashi in mammalian cells 
under conditions that promote Musashi target mRNA 
translation.   
We next sought to determine if endogenous Musashi 
associates with PABPC1 in mammalian cells under 
conditions of Musashi target mRNA de-repression and 
translation.  We have previously reported that 
differentiation of primary embryonic rat neuronal 
stem/progenitor cells or human SH-SY5Y neuroblastoma 
cells results in the de-repression and translation of Musashi 
target mRNAs (6,43).  When proliferating cells are switched 
to media to promote differentiation, mammalian Musashi is 
subject to activating phosphorylation on the sites conserved 
with the Xenopus  Musashi1 protein, resulting in translation 
of target mRNAs (43,44).  An assessment of Musashi1 
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activating phosphorylation thus serves as an indicator of de-
repression and translation of target mRNAs. 
 
We utilized the human SH-SY5Y neuroblastoma cell line 
and a human induced pluripotent stem cell line (iPSCs) to 
assess the interaction of PABPC1 under proliferating 
conditions where Musashi directs repression or under 
conditions where Musashi1 is phosphorylated to allow de-
repression and translation of target mRNAs through 
differentiation of SH-SY5Y cells or iPSCs along a neural 
progenitor lineage.  Two antibodies were found to 
immunoprecipitate human Musashi1.  One antibody 
(AbCam 52865) efficiently immunoprecipitated 
endogenous Musashi1 and weakly retained association of 
PABPC1 whereas a second antibody (AbCam 114107) 
immunoprecipitated both Musashi1 and Musashi2 and more 
effectively preserved association of PABPC1 (Figure 9A).  
We utilized the AbCam 114107 antibody for all subsequent 
immunoprecipitations.  When SH-SH5Y cells were cultured 
to promote differentiation, the differentiating SH-SY5Y 
cells exhibited a significant increase in Musashi1 activating 
phosphorylation (Figure 9B, pMsi1) without significant 
change in overall levels of Musashi1 (Figure 9B, Msi1).  
Notably, over three independent experiments, no 
statistically significant change in the levels of 
Musashi:PABPC1 interaction were observed when 
Musashi1 was immunoprecipitated from either proliferating 
or from differentiating SH-SY5Y cells (Figure 9C).  
Similarly, the AbCam 114107 antibody 
immunoprecipitated Musashi1 and co-associated PABPC1 
from either proliferating human iPSCs or iPSCs 
differentiated to adherent neural progenitor cells (Figure 
9D). When the iPSCs were differentiated to neural 
progenitor cells, a significant increase in activating 
Musashi1 phosphorylation was observed (Figure 9E).  Over 
three independent experiments, immunoprecipitation of 
endogenous Musashi1 revealed no significant changes in 
the level of co-associated PABPC1 in proliferating iPSCs 
(PSC) or in differentiated cell populations (Figures 8F).  We 
conclude that PABPC1 interaction persists with Musashi1 
under conditions of target mRNA de-repression and 
translation.  These findings are consistent with PABPC1 
interacting with Musashi1 to facilitate translation of 
Musashi-target mRNAs in differentiating cell contexts. 
 
Discussion 
In this study, we demonstrate that Musashi1 interacts with 
several members of the poly(A) binding protein family, 
including ePABP and PABPC1, to promote translational 
activation of target mRNAs.  As such our data necessitate a 
fundamental revision of the model that describes a 
repressive-only function for the Musashi interaction with 
poly(A) binding proteins.  Our mapping data indicate that 
Musashi1 possesses two domains for interaction with 
ePABP, while in reciprocal experiments Musashi1 was 
shown to interact with the C-terminal domain of both 
ePABP and PABPC1.  Our data further indicate that 
differential interaction of Musashi1 or Musashi2 with 
poly(A) binding proteins may underlie differences in their 
functional properties. 
 
We have previously shown that site-specific 
phosphorylation is required to facilitate de-repression and 
promote Musashi target mRNA translation, both in the 
oocyte system and mammalian cells (39,43,44).  In the 
oocyte, the initial “trigger” phosphorylation of these 
activating sites occurs via early Ringo/CDK-mediated 
phosphorylation (39).  Full activating Musashi1 
phosphorylation was shown to require feedback 
phosphorylation by MAP kinase signaling, a downstream 
effector of the Musashi target mRNA encoding Mos, a MAP 
kinase signaling activator  (39).  We found that full 
activating phosphorylation of Musashi1 is blocked in 
ePABP antisense-injected oocytes (Figure 3C), although 
synthesis of Ringo protein occurs normally in ePABP 
antisense-injected oocytes and the initial Ringo/CDK-
mediated “trigger” phosphorylation of Musashi1 (39) seems 
unperturbed.  The failure to achieve full Musashi1 
activation may be explained by the compromised 
polyadenylation of the Mos mRNA (Figure 4) and the 
consequent failure to attain robust activation of MAP kinase 
and the MAP kinase-dependent feedback amplification of 
Musashi1 phosphorylation (Figure 3D) (39).  We conclude 
that the loss of ePABP interaction with Musashi resulted in 
attenuation of translation of Musashi target mRNAs, 
including the mRNA encoding Mos, and that this 
compromised downstream MAP kinase signaling. 
 
Our mass spectrometry data suggest that the Musashi 
interactome undergoes dynamic regulation in response to 
progesterone stimulation.  Of note, the differential 
enrichment of two proteins, CPEB1 and PABPC1, 
exemplify the remodeling of Musashi mRNP complexes.  
We have previously reported that the interaction of 
Musashi1 with CPEB1 is specific, RNase1 insensitive (i.e. 
it does not simply occur via mRNA co-occupancy) and 
occurs via an indirect association (51).  Here, we see the 
interaction of Musashi1 with CPEB1 is restricted to 
immature oocytes.  The CPEB1 population undergoes 
significant degradation in response to progesterone 
stimulation (56), likely explaining the lack of a significant 
Musashi1 co-association in maturing oocytes.  A failure to 
detect PABPC1 in the immature oocyte data set while 
observing association in maturing oocytes likely reflects the 
low abundance of this protein isoform in the immature 
oocyte and the subsequent progesterone-dependent 
accumulation of PABPC1 in the maturing oocyte (48). 
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It is noteworthy that approximately one third (16/50) of the 
proteins detected as Musashi1 partner proteins in the oocyte 
are have been previously identified as partner proteins of the 
human Musashi2 protein (57).  Moreover, over half (9/16) 
belong to the “core” Musashi1 interactome that is shared 
between immature and maturing oocytes (Supplemental 
Table 4).  We speculate that these proteins may play a 
conserved role in controlling the assembly and/or function 
of Musashi mRNP complexes on target mRNAs.   
 
Consistent with repression of Musashi target mRNAs in 
immature oocytes, a number of the co-associating proteins 
are known to contribute to translational repression (Figure 
1A), including DDX6, LSM14A/B, PAT1 and EIF4ENIF1 
((58-61)).  While association with PAT1 decreases in 
maturing oocytes, the other proteins remain associated and 
it will be interesting in future studies to determine how their 
activity is modified within Musashi mRNP complexes to 
allow progesterone-dependent target mRNA translation.  
 
The increased interaction (approximately 2-fold) of ePABP 
with Musashi1 after progesterone-stimulation (Figure 2), 
also supports the idea that Musashi interactions with partner 
proteins are dynamically regulated in response to 
extracellular cues. The mechanism underlying differential 
ePABP co-association is unclear but several non-exclusive 
possibilities may be considered.  First, the increased ePABP 
interaction may represent ePABP recruitment to a 
previously unbound Musashi1 after progesterone 
stimulation.  We note that Musashi1 protein increases in 
response to progesterone potentially providing a reservoir 
of available targets for ePABP interaction (28).  Second, the 
two sites of interaction on Musashi1 may allow engagement 
of a second ePABP to a Musashi1 protein already bound to 
ePABP.  Third, the increase may represent multimerization 
of ePABP bound to Musashi1.   
 
We report a strong interaction of ePABP with Musashi C-
terminal amino acids 190-240 as well as weaker interaction 
with Musashi N-terminal amino acids 80-120 (Figure 5).  
Interestingly, three proteins have now been demonstrated to 
interact with the C-terminal amino acids 190-240 region of 
Musashi1: PABPC1 (27); GLD2 (46); and ePABP (this 
study).  GLD2 interacts strongly with amino acids 190-220 
of the Musashi1 protein (46) while this same region 
interacted poorly with ePABP (Figure 5C).  By contrast, 
ePABP interacted strongly with amino acids 190-240, 
interacted weakly with amino acids 190-230 and failed to 
interact with amino acids 210-240, indicating that ePABP 
has a larger footprint of interaction across this region of the 
Musashi1 protein (Figure 5C).  Whether GLD2 and either 
ePABP or PABPC1 can interact simultaneously to the same 
Musashi1 protein remains to be determined.  Although 
antisense knockdown experiments indicate that all three 
proteins promote Musashi-dependent translational 
activation, their relative contributions will require 
generation of point mutations that selectively attenuate their 
interactions within the 190-240 region of Musashi1.  With 
regard to the poly(A) binding proteins, our data indicate an 
attenuation of Musashi target mRNA polyadenylation in 
ePABP-depleted oocytes (Fig. 4). These findings support a 
role for ePABP in augmenting the ability of GLD2 to 
promote progesterone-dependent polyadenylation and/or 
protecting newly extended poly(A) tails to facilitate 
Musashi target mRNA translation. 
 
Employing yeast two hybrids assays, Musashi1 was shown 
to interact directly with the C-terminal domains of ePABP 
and PABPC1 (Figure 6).  Contrary to a previous report (27), 
no RNA-independent interaction of Musashi1 with RRMs 1 
and 2 of either ePABP or PABPC1 was observed.  One 
possible explanation for the discrepancy between these 
findings is that the prior study employed co-
immunoprecipitation in the presence of RNase A (a 
pyrimidine-specific endoribonuclease) which may not have 
fully degraded mRNAs in the sample, thus allowing 
recovery of Musashi1 and PABP due to mRNA transcript 
co-occupancy rather than protein:protein interaction.  
Indeed, in the yeast two hybrid assay, an interaction with 
full length Musashi1 and RRMs 1 and 2 was seen, but this 
was abolished when an RNA binding mutant form of the 
PABPC1 RRM 1 and 2 domain was employed.  Of note, the 
RNA binding mutant form of the PABPC1 RRM 1 and 2 
domain was still able to interact with eIF4G (Figure 6).  
Since Musashi1 interacts with the C-terminal domain of 
PABPs and not the eIF4G-interacting RRMs 1 and 2, our 
data do not support a direct competition between Musashi1 
and eIF4G for the same site of interaction on PABPs as 
proposed (27).  Nonetheless, it is possible that Musashi1 
interaction with the C-terminal domain of PABPC1 or 
ePABP mediates an indirect attenuation of eIF4G binding 
through a conformation change.   
 
Irrespective of the precise mechanism of repression, our 
findings add to the current understanding of Musashi-
dependent translational control and extend the existing 
model in several ways.  First, Musashi1 interaction with 
PABPs is not simply limited to exerting repression.  
Musashi1 remains associated with ePABP and PABPC1 
under conditions of Musashi target mRNA de-repression 
and translational activation (Figs 1, 2, and 9).  Thus the 
regulatory switch from mRNA repression to translational 
activation does not require dissociation of PABPs, but 
rather stimulus-dependent modification of Musashi activity 
in the presence of retained PABP association.  Second, 
association of PABPs with Musashi is required to promote 
target mRNA translational activation in response to 
appropriate differentiation cues.  Like GLD2, the other 
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characterized co-factor activator (46), PABPs remain 
constitutively associated with Musashi1 irrespective of 
whether target mRNAs are repressed or translated.  Thus, 
the activity of the regulatory complex must be controlled in 
a stimulus-dependent manner.  While this switch in 
regulatory function involves site-specific phosphorylation 
of the Musashi1 and Musashi2 proteins, it may also require 
additional modification of co-associated factors, perhaps 
including the PABPs (62,63) to facilitate formation of a 
regulatory complex capable of stimulating de-repression 
and translation of Musashi target mRNAs.   
 
Musashi1 and Musashi2 have been shown to act 
redundantly in several physiological systems, including 
neural stem cell self-renewal and Xenopus oocyte 
maturation, as well as pathologically in propagation of 
colon cancer stem cell function (23,30,44,64).  However, 
Musashi1 and Musashi2 have been reported to have distinct 
functions in pancreatic cells (65) and a differential ability to 
support Zika virus replication (42).  We show here that 
Musashi1 and Musashi2 have overlapping but non-identical 
functions in the oocyte, as Musashi2 functions less 
effectively than the Musashi1 isoform in promoting 
maturation.  Consistent with the idea of non-identical 
functions, several reports have demonstrated isoform-
specific interaction with partner proteins.  Musashi1, but not 
Musashi2, can interact with Lin28 (45) suggesting that 
regulation of miRNA biosynthesis may be a unique property 
of Musashi1.  Similarly, mammalian GLD2 can interact 
with mammalian Musashi1 but not mammalian Musashi2, 
although the functional consequence of this altered GLD2 
interaction has yet to be established (46).  To add to this list 
of isoform-specific differences, we show here that ePABP 
and PABPC1 have dramatically reduced interaction with 
Musashi2 compared to Musashi1 and that this reduced 
interaction correlates with diminished capacity to promote 
cell cycle progression during oocyte maturation.  Indeed, 
domain swap experiments revealed that substitution of 
Musashi2 amino acids 190-240 for the corresponding 
Musashi1 sequence recapitulated full activity to the 
chimeric Musashi2 protein (Figure 7).  Our data support a 
model where differential interactions with partner proteins 
underlie functional distinctions between the Musashi1 and 
Musashi2 isoforms. 
 
In summary, we provide evidence for a dynamic interaction 
of Musashi with members of the poly(A) binding protein 
family and demonstrate that poly(A) binding protein 
interaction with Musashi is necessary to promote target 
mRNA translation, in addition to mediating repression.  
These findings extend earlier models of Musashi-dependent 
translational control and provide new insights into the 
regulation of co-associated factor interactions as Musashi 
switches from a repressor to an activator of translation.  Our 
results also highlight important Musashi isoform specific 
difference in partner protein interactions that can modulate 
the ability of Musashi1 and Musashi2 to control the 
translational output of target mRNAs.   
 
Experimental Procedures 
Oocyte Culture and Microinjections. 
Dumont Stage VI immature Xenopus laevis oocytes were 
isolated and cultured as described previously (66). Oocytes 
were microinjected using a Nanoject II Auto-Nanoliter 
Injector (Drummond Scientific). mRNA for oocyte 
injection was made by linearization of the plasmid and in 
vitro transcription using SP6 (Promega) or T7 (Invitrogen) 
RNA polymerase as appropriate. Oocytes were stimulated 
to mature with 2µg/ml progesterone. The appearance of a 
white spot on the animal pole was used to score the rate of 
oocyte maturation as it indicates germinal vesicle (nuclear) 
breakdown (GVBD). Where indicated, progesterone-
stimulated oocytes were segregated when 50% of the 
oocytes completed GVBD (GVBD50) into those that had not 
(-) or had (+) completed GVBD. In the event of ambiguous 
morphology, oocytes were fixed for 10 minutes in ice cold 
10% trichloroacetic acid and dissected for the presence or 
absence of a germinal vesicle. Animal protocols were 
approved by the UAMS Institutional Animal Care and Use 
committee, in accordance with Federal regulations. 
 
Oocyte Lysis and Sample Preparation.  
For co-association experiments, oocytes were lysed in 
10µl/oocyte of ice cold NP40 lysis buffer (1% NP40, 20mM 
Tris pH 8.0, 137mM NaCl, 10% glycerol, 2mM EDTA, 
50mM NaF, 10mM Sodium Pyrophosphate, 1mM PMSF, 
1x Protease Inhibitor (Thermo Fisher Scientific)). Yolk and 
cell debris were removed by centrifugation at 12,000+ rpm 
for 10 minutes in a refrigerated tabletop centrifuge at 4˚C.  
For each sample, half oocyte equivalents of lysate were 
prepared in NuPAGE sample loading buffer and 
electrophoresed through a 10% NuPAGE gel (Invitrogen).  
Where required, a portion of the lysate was transferred 
immediately following lysis to STAT-60 (Tel-Test, Inc) for 
RNA extraction using the manufacture’s protocol followed 
by a subsequent purification by precipitation in 4M LiCl at 
-80˚C for 30 minutes and centrifugation at 12,000rpm for 
10 minutes in a refrigerated tabletop centrifuge.   
 
Pulldown and RNase Treatment.  
Oocytes were injected with 57.5 ng of each in vitro 
transcribed mRNA and incubated for 16h at 18˚C. Lysates 
were prepared as described above. 300µl of oocyte lysate 
was added to 450µl ice cold NP40 lysis buffer and incubated 
with 50µl of 50% glutathione sepharose conjugated bead 
slurry (GE) at 4˚C for 6h with gentle rotation. Beads were 
then gently pelleted by centrifugation at 500 rpm for 5 
minutes; the supernatant was removed and replaced with 
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500µl fresh NP40 lysis buffer and the beads inverted to mix 
and the buffer then removed. This process was repeated 3 
times at 4˚C. On the third wash, 200U of RNase1 (Ambion) 
was added and incubated for 15 minutes at 37˚C. Following 
final centrifugation, all NP40 was removed and 50µl of 
NuPAGE sample loading buffer (Invitrogen) was added. 
Beads were incubated for 10 minutes at 70˚C, then crushed 
by centrifugation at 12,000 rpm for 10 minutes. Finally, 
45µl of the sample was loaded per each lane of a 10% 
NuPAGE gel (Invitrogen) and electrophoresed.  
 
Mammalian Cell Culture and Immunoprecipitation of 
endogenous Musashi.  
The SH-SY5Y human neuroblastoma cell line (ATCC) was 
cultured in DMEM/F12 medium with 10% fetal bovine 
serum (Thermo Fisher Scientific) and human induced 
pluripotent stem cells (iPSCs, #KYOU-DXR0109B, 
ATCC) were cultured in Essential 8 Medium (Thermo 
Fisher Scientific), on vitronectin-coated dishes (Thermo 
Fisher Scientific) with 5% CO2, as per the supplier's 
protocol.  Neuronal differentiation was induced in SH-
SY5Y cells through 1 week culture in retinoic acid-
containing medium [DMEM/F12 with 1x B27 with vitamin 
A supplement (Thermo Fisher), further supplemented with 
1 µM retinoic acid (Sigma)].  Differentiation to neural stem 
cells was induced in human iPSCs through 1 week culture 
in PSC Neural Induction Medium on vitronectin-coated 
dishes (Thermo Fisher Scientific).  Neural progenitor cells 
exhibited greater than 10-fold loss of pluripotency gene 
expression (Nanog) and gain of neural progenitor gene 
expression (sox1), as per the suppliers protocol (Thermo 
Fisher Scientific).  Cell lysate was prepared after rinsing the 
cells twice with cold DPBS (Thermo Fisher Scientific) 
followed by lysis with NP-40 lysis buffer (250-500 µl per 
10 cm dish) and clearing through centrifugation.  Musashi1 
or Musashi1/2 were immunoprecipitated from cleared cell 
lysate (100-250 mg) with 10µg antibody [Anti-Musashi1 
#ab52865 (AbCam) or Anti-Musashi2 #ab114107 (which 
also immunoprecipitates Musashi1, AbCam)] or Normal 
Rabbit IgG (control, #12-370, Millipore) and 20µl Protein 
A Agarose (#ab193254, AbCam) with overnight incubation 
at 4oC with rocking. Immuno-complexes were washed twice 
with lysis buffer and dissociated at 100oC, 10 min, with 
NuPAGE gel loading buffer (Thermo Fisher Scientific) 
with added 10 mM DTT and separated by electrophoresis 
(NuPAGE, Thermo Fisher Scientific). 
 
Western Blotting.  
Following electrophoresis, NuPAGE gels were transferred 
to a 0.2µm-pore-size nitrocellulose membrane (Protran; 
Midwest Scientific). The membrane was blocked with 5% 
non-fat dried milk or 1% BSA in TBST (20mM Tris pH 7.5, 
150mM NaCl, 0.05% Tween20) for 60 min at room 
temperature, or overnight at 4˚C. Following incubation with 
primary antibody, filters were washed 3x10 minutes in 
TBST, incubated with horseradish peroxidase-conjugated 
secondary antibody, or Protein A HRP-conjugate (#12291, 
Cell Signaling) then washed 3x10 minutes in TBST. Blots 
were developed using enhanced chemiluminescence in a 
Fluorchem 8000 Advanced Imager (Alpha Innotech Corp.). 
Western blots were quantified using Fluorchem FC2 
software (Alpha Innotech Corp.) 
 
Antibodies.  
The Xenopus ePABP antibody (67) was used at 1:5000 
dilution. Antisera for phosphorylation-specific Musashi1 
S322 (39) was used at 1:1000 dilution.  The Xenopus Ringo 
antibody was a generous gift from Dr. Angel Nebreda and 
used at 1:1000 dilution.  Additional antibodies used for 
Immuno-detection were Anti-GAPDH (1:5000, #AM4300, 
Ambion/Life Technologies), Anti-GST (1:5000, #SC-138, 
Santa Cruz), Anti-p44/42 MAPK (ERK1/2) (1:1000, #4695, 
Cell Signaling), Anti-Phospho p44/42 MAPK (ERK1/2) 
(1:1000, #4370, Cell Signaling), Anti-Musashi (1:500, 
#2154, Cell Signaling), Anti-Musashi1 (1:1000, #ab21628, 
AbCam), Anti-Musashi2 (1:000, #ab50829, AbCam), Anti-
PABP1 (1:000, #4992, Cell Signaling) and Anti-Tubulin 
(1:5000, #ab7291, AbCam).  All working antibody 
preparations were made in TBST + 0.5% non-fat milk or 
0.1% BSA.   
 
Polyadenylation Assays.  
cDNAs for polyadenylation assays were synthesized using 
RNA ligation-coupled PCR as described (52).  The increase 
in PCR product length is specifically due to extension of the 
poly[A] tail (28,52,53).  The same reverse primer P1’ was 
used for all reactions and has the sequence: 5’-
GCTTCAGATCAAGGTGACCTTTTT-3’.  The Mos 
forward primer has the sequence: 5’-
GCAAGGATATGAAAAAAAGATTTC-3’.  The Nrp1b 
(Xenopus Musashi1) primer has the sequence 5’-
CAATACTGCAATGTACAATGTACTGC-3’. The Cyclin 
A1 primer has the sequence: 5’-
CATTGAACTGCTTCATTTTCCCAG-3’.  Deducting the 
size of the mRNA specific 3’ UTR sequence prior to the site 
of poly[A] addition and the size of the ligated P1 DNA 
oligonucleotide from the mode of the PCR product size in 
immature oocytes, we deduce the Mos mRNA has ~60 
adenylate tail; the Nrp1b mRNA has ~60 adenylate tail 
while the cyclin A1 mRNA has ~30 adenylate tail in control, 
immature oocytes. For Mos and Nrp1b the poly[A] tails are 
extended by approximately 60 and 70 adenylate residues, 
respectively, after 3 hours of progesterone stimulation (see 
Figure 4B-D). 
 
Antisense Oligodeoxynucleotide Injections and Rescue.  
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Antisense oligodeoxynucleotide 5’- 
CGGCTCCGGTTGCATTCATGTTTG -3’ was used to 
target endogenous ePABP mRNA (49). Antisense 
oligodeoxynucleotides targeting Xenopus Musashi1 and 
Musashi2 have been described previously (29). Control 
oocytes were injected with randomized oligonucleotide 
with the sequence 5’-
TAGAGAAGATAATCGTCATCTTA-3’ (36). A total of 
100ng of antisense oligonucleotides was injected for each 
condition and oocytes were incubated at 18oC for 16 hours. 
For Musashi rescue assays, Musashi1/2 antisense injected 
oocytes were subsequently injected with 23ng RNA 
encoding wild type Musashi1, Musashi2 or the chimeric 
Musashi2 protein that contained the Musashi1 ePABP 
binding domain. The oocytes were then incubated for 1 hour 
at room temperature to allow expression of the protein, then 
stimulated to mature with progesterone. For rescue of 
ePABP antisense injected oocytes, oocytes were co-injected 
with 57.5ng of wobble Xenopus ePABP mRNA, which is 
resistant to the antisense oligos (49) or Xenopus PABPC1 
mRNA which is not targeted by the ePABP 
oligonucleotides.  Following overnight incubation, oocytes 
were stimulated with progesterone and the extent of GVBD 
scored. 
 
Liquid Chromatography Coupled Tandem Mass 
Spectrometry. 
We used mass spectrometry to identify Musashi1-
associated protein complexes. 240 oocytes were each 
injected with 115ng mRNA encoding GST-XMsi1 or GST 
alone.  We estimate by western blot analysis that this results 
in a 5-10 fold overexpression of GST-XMsi1 to the 
endogenous Musashi1 protein.  Following overnight 
incubation, the oocytes from each injection were split into 2 
separate pools and either left untreated or stimulated with 
progesterone.  All oocytes were collected when 
progesterone stimulated samples had reached GVBD50 and 
lysed in ice cold Tween 20 buffer (0.1% Tween 20, 20mM 
Tris pH 8.0, 137mM NaCl, 10% glycerol, 2mM EDTA, 
50mM NaF, 10mM Sodium Pyrophosphate, 1mM PMSF, 
1x Protease Inhibitor (Thermo Fisher Scientific)).  A 
glutathione pulldown for each condition was then 
performed.  600µl of oocyte lysate was added to 250µl of 
50% glutathione sepharose conjugated bead slurry (GE) at 
4˚C for 6h with gentle rotation.  Beads were then gently 
pelleted by centrifugation at 500 rpm for 5 minutes; the 
supernatant was removed and replaced with 1ml fresh 
Tween 20 lysis buffer.  This process was repeated 3 times 
at 4˚C and following the final centrifugation, all lysis buffer 
was removed and 50µl of LDS sample loading buffer 
(Invitrogen) was added and incubated overnight at 4˚C for 
6h with gentle rotation. Beads were incubated for 10 
minutes at 70˚C, then crushed by centrifugation at 12,000 
rpm for 10 minutes. Finally, 45µl of the sample was loaded 
per each lane of a 10% NuPAGE gel (Invitrogen) and 
electrophoresed.  Following electrophoresis, the gel was 
fixed by 5 minute incubation with 10% acetic acid and 16% 
methanol at room temperature.  Following incubation, 
fixative was replaced with deionized water and microwaved 
for 45s.  The water was poured off and replaced with 
GelCode Blue (Pierce) and microwaved again for 30s to 
begin staining.  The gel was then gently rocked for 30 
minutes at room temperature.  Finally, the GelCode Blue 
was replaced with 1% acetic acid and gently rocked for 1 
hour.  Protein gel bands were then excised and subjected to 
in-gel trypsin digestion.  Gel slices were destained in 50% 
methanol (Thermo Fisher Scientific), 100mM ammonium 
bicarbonate (Sigma-Aldrich), followed by reduction in 
10mM Tris[2-carboxyethyl]phosphine (Pierce) and 
alkylation in 50 mM iodoacetamide (Sigma-Aldrich).  Gel 
slices were then dehydrated in acetonitrile (Fisher), 
followed by addition of 100 ng porcine sequencing grade 
modified trypsin (Promega) in 100 mM ammonium 
bicarbonate (Sigma-Aldrich) and incubation at 37oC for 12-
16 hours.  Peptide products were then acidified in 0.1% 
formic acid (Pierce).  Tryptic peptides were separated by 
reverse phase Jupiter Proteo resin (Phenomenex) on a 100 x 
0.075 mm column using a nanoAcquity UPLC system 
(Waters).  Peptides were eluted using a 40 min gradient 
from 97:3 to 35:65 buffer A:B ratio. [Buffer A = 0.1% 
formic acid, 0.5% acetonitrile; buffer B = 0.1% formic acid, 
75% acetonitrile.]  Eluted peptides were ionized by 
electrospray (1.9 kV) followed by MS/MS analysis using 
collision-induced dissociation on an LTQ Orbitrap Velos 
mass spectrometer (Thermo).  MS data were acquired using 
the FTMS analyzer in profile mode at a resolution of 60,000 
over a range of 375 to 1500 m/z.  MS/MS data were 
acquired for the top 15 peaks from each MS scan using the 
ion trap analyzer in centroid mode and normal mass range 
with a normalized collision energy of 35.0.  Proteins were 
identified by searching against the UniprotKB database 
restricted to Homo sapiens (177,579 entries) using 
MaxQuant (version 1.5.3.8, Max Planck Institute) with a 
parent ion tolerance of 3 ppm and a fragment ion tolerance 
of 0.5 Da, fixed modification of carbamidomethyl on C, and 
variable modifications including oxidation on M, and 
Acetyl on peptide N-terminus.  Scaffold (Proteome 
Software) was used to verify MS/MS based peptide and 
protein identifications.  Peptide identifications were 
accepted if they could be established with less than 1.0% 
false discovery by the Scaffold Local FDR algorithm and 
contained at least 2 identified peptides.  Protein 
probabilities were assigned by the Protein Prophet 
algorithm (68).  The pulldown and MS experiments were 
repeated in triplicate and a p-value representing the t-test 
significance of an interaction with GST-Musashi1 versus 
the GST moiety alone after correction of assigned spectral 
hits for molecular weight of the target protein (log2 
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normalized spectral abundance factor, (50)) was derived for 
each identified protein.  Fifty proteins were found to 
specifically interact with Musashi1 (Supplementary Table 
1).  The mass spectrometry proteomics data have been 
deposited to the ProteomeXchange Consortium via the 
PRIDE partner repository (69) with the dataset identifier 
PXD013585 and 10.6019/PXD013585. Gene set 
enrichment analysis (70) was used to query the molecular 
signatures database (MSigDB) for the top ten gene ontology 
molecular functions.  
 
Yeast two hybrid assays (Y2H) 
Y2H analysis was performed in strain L40 as described in 
(71), with the strength of interaction being scored by the 
extent of blue color apparent within a fixed time. 
 
Statistical Analysis.  
All quantitated data are presented as the mean +/- S.E. 
Statistical significance was assessed by one way Analysis 
of Variance followed by the Bonferroni post hoc test or by 
Student’s t-test when only two groups were compared.  A 
probability of p < 0.05 was adopted for statistical 
significance.  
 
Plasmids and plasmid Construction 
The derivation of a number of the constructs used in this 
study has been previously described.  These include GST-
XMsi1 (30); GST-XMsi2, GST-mMsi1, GST-mMsi2, 
GST-mMsi1 D190-234, GST-N-term XMsi1, GST-C-term 
XMsi1, GST-XMsi1 D200-210, GST-XMsi1 D200-220, 
GST-XMsi1 190-240, GST-XMsi1 190-230, GST-XMsi1 
190-220, GST-XMsi1 210-240 and pXen GFP (46); 
XePABP (wobble) and XPABPC1 (49); LexA-MS2, PAB 
1-2, PAB-Rd (RRMs 1 and 2 RNA binding mutant), PAB 
3-4, PAB-Ct and pACT-IRP and pACT-4GNt (71); BTM 
e1-2, BTM e3-4 and BTM-eCt (67). Plasmid constructs 
generated exclusively for this study are detailed in Table 1 
below: 
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Table 1:  Plasmid construction. 
The technique, strategy and where appropriate primer sequences used to generate the plasmid constructs utilized in this 
study are indicated.  PCR fragment generation: Template was subjected to PCR amplification using the indicated primers. 
Resulting PCR fragments were then purified using agarose gel electrophoresis followed by clean up using a QIAquick Gel 
Extraction Kit (Qiagen). Next, the fragments and destination vector were digested using the indicated restriction enzymes 
and again purified and cleaned up using gel electrophoresis and the QIAquick kit. The fragment and vector were then ligated 
using the T7 Quick Ligase (New England Biolabs). Finally, the ligated fragment/vector was used to transform competent 
DH5-alpha E. coli.  PCR-directed mutagenic deletion: Template was subjected to PCR amplification of the entire plasmid. 
Primer sequence “looped out” the desired sequence for deletion.  Restriction fragment subcloning: Template DNA and 
destination vector were separately digested with the indicated restriction enzymes and the desired fragments isolated and 
purified using agarose gel electrophoresis followed by clean up using a QIAquick Gel Extraction Kit (Qiagen). The fragment 
and vector were then ligated using the T7 Quick Ligase (New England Biolabs). Finally, the ligated fragment/vector was 
used to transform competent DH5-alpha E. coli. 
 
Construct Methodology  
GST-XMsi1 
1-179 
+)5’- GCGCGATCGATGGCGACAGAAGCGCCCCAG -3’  
(-)5’- CGCGCTCGAGCTAAACCATTTTATTGTTGAT -3’ 
Technique: PCR fragment generation 
Template: GST-XMsi1 
Vector: pXen1 
Restriction Enzymes: 5’ ClaI 3’ XhoI 
GST-XMsi1 
180-347 
(+)5’- GCGCGATCGATGGCGTGTAAGAAGGCCCAGCC -3’ 
(-)5’- CGCGCGTCTAGATCAGTGGTAGCCGTTGGTAAAAGC -3’ 
Technique: PCR fragment generation 
Template: GST-XMsi1 
Vector: pXen1 
Restriction Enzymes: 5’ ClaI 3’ XbaI 
GST-XMsi1  
RRM1 
(+)5’- GCGCGATCGATGGCGACAGAAGCGCCCCAG -3’ 
(-)5’- GCGCGTCTAGACTACTTGGGTTGAGCTCTACGAGGAAA -3’ 
Technique: PCR fragment generation 
Template: GST-XMsi1 N-terminal 
Vector: pXenI 
Restriction Enzymes: 5’ ClaI 3’ XbaI 
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GST-XMsi1  
RRM2 
(+)5’- GCGCGATCGATGGTAACACGGACAAAGAAGATT -3’ 
(-)5’- GCGTCTAGATCGGCCTCTCACAGACCCTGTTG -3’ 
Technique: PCR fragment generation 
Template: GST-XMsi1 N-terminal 
Vector: pXen1 
Restriction Enzymes: 5’ Cla1 3’ Xba1 
GST-N-
terminal 
XMsi1 ∆80-
120 
(+)5’- GGAGTGGACAAAGTTTTGGCTACAGTTGAAGATGTGAAAC -3’ 
(-)5’- GGT TCACATCTTCAACTGTAGCCAAAACTTTGTCCACTCC -3’ 
Technique: PCR-directed mutagenic deletion 
Template: GST-XMsi1 N-terminal 
Vector: pXen1 
pACT-
XMsi1 
(+)5’- GCGCCATGGAGACAGAAGCGCCCCAGCC -3’ 
(-)5’- GCGGAATTCTCAGTGGTAGCCGTTGGTAAAAGC -3’ 
Technique: PCR fragment generation 
Template: GST-XMsi1  
Vector: pACT2 
Restriction Enzymes: 5’ Nco1 3’ EcoR1 
pACT-
XMsi1-Nt 
(1-198) 
(+)5’- GCGCCATGGAGACAGAAGCGCCCCAGCC -3’ 
(-)5’- GCGGAATTCTCAGCCTCTCACAGACCCTGTTGGTGAC -3’ 
Technique: PCR fragment generation 
Template: GST-XMsi1  
Vector: pACT2 
Restriction Enzymes: 5’ Nco1 3’ EcoR1 
pACT-
XMsi1-Ct 
(199-347) 
(+)5’- GCGCCATGGAGCGATCTCGGGTCATGCTATATGG -3’ 
(-)5’- GCGGAATTCTCAGTGGTAGCCGTTGGTAAAAGC -3’ 
Technique: PCR fragment generation 
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Template: GST-XMsi1  
Vector: pACT2 
Restriction Enzymes: 5’ Nco1 3’ EcoR1 
GST-XMsi2 
Chimera 
 
(A) 5’-  GCGCATCGATGGAGGCAGATGGGAGC -3’ 
(B) 5’- CACAGACCCTGTTGGTGACATGACTTCCTTAGGCTGTGC -3’ 
(C) 5’- GCACAGCCTAAGGAAGTCATGTCACCAACAGGGTCTGTG -3’ 
(D) 5’- AAAACCTGGAAACTGATAGCTATATCCAGGTGCAATGCC -3’ 
(E) 5’- ATTGCACCTGGATATAGCTATCAGTTTCCAGGTTTTCC  -3’ 
(F) 5’- GCGCCTCGAGTCAATGGTATCCATTTG -3’ 
Primers A and B were combined with pXen-XMsi2 to PCR the N-terminal 189 
amino acids of XMsi2. Primers E and F were combined with pXen-XMsi2 to 
PCR the C-terminal 163 amino acids. Primers C and D were combined with 
pXen-XMsi1 to PCR the ePABP binding domain (aa190-240). The products from 
these 3 PCRs were then combined along with primers A and F to create the 
chimeric PCR product. This product was then digested with 3’-ClaI and 5’-XhoI 
then ligated into pXen1. 
GST-
XPABPC1 
(+)5’- GCGCATCGATATGAATCCCAGTGCTCCCAGC -3’ 
(-)5’- GCGCCTCGAGTTAAGCAGTTGGCACTCCAGTTGCA -3’ 
Technique: PCR fragment generation 
Template: pET XPABPC1-Flag (49) 
Vector: pXen1 
Restriction Enzymes: 5’ Cla1 3’ Xho1 
GFP XMsi1 Technique: Restriction fragment subclone 
Template: pXen XMsi1 (30) 
Vector: pXen GFP (46) 
Restriction Enzymes: 5’ Cla1 3’ Xba1 
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GFP XMsi2 Technique: Restriction fragment subclone 
Template: pXen XMsi2 (46) 
Vector: pXen GFP (46) 
Restriction Enzymes: 5’ Cla1 3’ Xho1 
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Figure Legends 
Figure 1: Mass spectrometry identification of the Musashi1 interactome.  
(A) Oocytes were injected with mRNA encoding GST-XMsi1 or the GST moiety alone. The injected oocytes were incubated 
overnight to express the introduced proteins. Following incubation, 1/2 of the GST and 1/2 of the GST-XMsi1 injected 
oocytes were stimulated to mature with progesterone and the rest left untreated (Immature). When 50% of oocytes have 
reached GVBD, protein lysates were prepared, partially purified over glutathione sepharose and subjected to mass 
spectrometry. The experiment was repeated on three separate occasions.  A total of 50 proteins were identified that 
specifically interacted with Musashi1.  Of these, 21 only interacted significantly with Musashi1 in immature oocytes, 10 
only interacted significantly with Musashi1 in progesterone-stimulated oocytes, while 19 were common to both conditions.  
The identified proteins for each category are indicated.  (B) Gene set enrichment analysis was performed on the 50 
interacting proteins and the top ten significant gene ontology molecular functions are shown graphically. 
 
Figure 2: The RNA-independent association of ePABP with Musashi1 increases during progesterone-stimulated 
oocyte maturation.  
(A) Oocytes were injected with mRNA encoding GST-XMsi1 or the GST moiety alone. The injected oocytes were incubated 
overnight to express the introduced proteins. Following incubation, 2/3 of GST-XMsi1 injected oocytes were stimulated to 
mature with progesterone and the rest left untreated (Immature). When 50% of oocytes have reached GVBD, lysate was 
prepared from segregated oocytes that had not (-) or had (+) completed progesterone-stimulated GVBD as well as time 
matched immature oocytes (I). Lysates were then subjected to GST-pulldown and treatment with RNase1. Protein co-
association was visualized by western blotting with ePABP (a-ePABP) and GST (a-GST) antibodies. GST-XMsi1 
associates with ePABP in an RNA independent manner (arrowhead). The position of molecular weight markers are indicated 
to the left of each panel. (B) The composite results of three independent experiments reveals increased association of ePABP 
with Musashi1 following progesterone stimulation. The data was normalized to the levels of ePABP association with GST-
XMsi1 in immature oocytes (100% of XMsi1) and for recovered GST-fusion protein levels in each sample.  * indicates 
p<0.05; ns, not significant. 
 
Figure 3: Knockdown of ePABP blocks progesterone-stimulated signaling pathways downstream of Musashi that 
lead to robust MAP kinase activation and oocyte maturation. 
(A) Oocytes were injected with antisense oligonucleotides targeting Musashi1/2 (Msi AS) or a scrambled control 
oligonucleotide (Con AS). Following overnight incubation, the Msi AS-injected oocytes were re-injected with water (no 
rescue), RNA encoding GST-XMsi1 or RNA encoding wobble ePABP and then stimulated to mature with progesterone. 
Maturation was scored when ~50% of GST-XMsi1 injected oocytes had reached GVBD.  The combined data of 3 
independent experiments is shown. ** indicates p<0.01.  (B) Oocytes were injected with antisense oligonucleotides targeting 
ePABP (ePABP AS) or a scrambled control oligonucleotide (Con AS). Following overnight incubation, the ePABP AS-
injected oocytes were re-injected with water (no rescue), RNA encoding wobble ePABP (which is not targeted by ePABP 
AS) or RNA encoding GST-XMsi1 and then stimulated to mature with progesterone. Maturation was scored when ~50% 
of wobble ePABP injected oocytes had reached GVBD.  The combined data of 3 independent experiments is shown. * 
indicates p<0.05.  (C) Oocytes were co-injected with RNA encoding GST-Musashi1 (to facilitate analysis of Musashi1 
activation status) and either scramble or ePABP antisense oligonucleotides (AS) as indicated and western blot analyses of 
the indicated components of the oocyte signaling cascade were performed from untreated immature (I) or progesterone-
stimulated oocytes.  For scramble-injected oocytes, oocytes were segregated at GVBD50 based on whether they had not (-) 
or had (+) completed GVBD.  ePABP antisense injected oocytes did not mature in response to progesterone and so were 
harvested when scramble-injected oocytes reached GVBD50.  Endogenous ePABP, Ringo, MAP kinase (MAPK) and tubulin 
(an internal loading control) were analyzed as indicated.  The activation status of endogenous MAP kinase was assessed 
with a phosphorylation (activation)-specific antibody (pMAPK). Ectopically expressed, GST tagged Musashi1 was detected 
with GST antibodies (Msi1) and phospho-specific Musashi1 antibodies were used to assess Musashi1 activation status 
(pMsi1).  The position of molecular weight markers are indicated to the left of each panel. (D) Schematic showing the early 
signaling pathway and positive feedback amplification loop leading to full Musashi activation and oocyte maturation 
(germinal vesicle breakdown, GVBD).  The observed ePABP antisense effects on progesterone signaling (panel C) are 
consistent with a block coincident with Musashi function and attenuated translation of the Musashi target mRNA, Mos, 
(which encodes the primary activator of MAPK signaling in the oocyte, see Discussion). 
 
Figure 4: Antisense oligonucleotides targeting ePABP attenuate progesterone-stimulated polyadenylation of 
Musashi target mRNAs. 
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(A) A representative experiment analyzing the poly[A] length assay of the Musashi target mRNAs, Mos and Nrp1b 
(Musashi-1).  A retardation in migration rate of the PCR products is indicative of poly[A] tail polyadenylation and 
elongation (52,53).  Polyadenylation (square brackets) of early class Mos and Nrp1b mRNAs, as well as they late class 
cyclin A1 mRNA, is seen in both uninjected and scrambled control oligonucleotide-injected oocytes treated with 
progesterone.  Oocytes injected with ePABP antisense oligonucleotides show attenuated polyadenylation of the Mos and 
Nrp1b mRNA populations (indicated by a smaller mode value of PCR product lengths).  By contrast, a full block of Mos 
and Nrp1b polyadenylation is seen in the Msi1/2 antisense oligonucleotide-injected oocytes.  The progesterone-stimulated 
polyadenylation of the late class cyclin A1 mRNA is inhibited in both ePABP and Msi1/2 antisense-treated oocytes, 
consistent with the observed block to oocyte maturation.  (I) indicates immature oocytes, (-) indicates progesterone-
stimulated oocytes harvested prior to GVBD, (+) indicates progesterone stimulated oocytes which had completed GVBD.  
Since neither Musashi or ePABP antisense–injected oocytes completed GVBD, samples were harvested when control, 
scramble antisense-injected oocytes reached GVBD50. The position of DNA size markers are shown to the left of the panels. 
(B-D) Graphic representation of the extent of progesterone-stimulated polyadenylation seen in panel A at the 3 hr pre-
GVBD timepoint (-) for Scramble (control) or ePABP AS oocytes.  The dashed lines represent the distribution of PCR 
product size in immature oocytes (Imm); solid lines are the distribution of PCR product size in progesterone-stimulated 
oocytes prior to GVBD. The grey lines are scrambled, control oligonucleotide-injected oocytes. Red lines represent ePABP 
antisense-injected oocytes. The peaks indicate the mode of the population of mRNA lengths. The shift of the peak between 
immature (dashed line) and progesterone-stimulated oocytes (solid line) to a larger size is indicative of mRNA 
polyadenylation.  Panel B, Mos mRNA polyadenylation; panel C, Nrp1b mRNA polyadenylation; and panel D, Cyclin A1 
mRNA polyadenylation. 
  
Figure 5: Deletion mapping reveals two ePABP interaction domains within amino acids 80-120 and 190-234 of the 
Musashi1 protein. 
(A) Oocytes were injected with mRNA encoding GST tagged wild-type or mutant Musashi constructs as indicated and 
ePABP interaction assessed after GST-pulldown and RNase1 treatment. For all mapping experiments, injection of the GST 
moiety alone served as a negative control. Horizontal bars schematically represent the Musashi constructs and the relative 
level of ePABP interaction indicated as a percentage of that observed with wild-type Xenopus Musashi1 as quantified by 
densitometry and normalized for the amount of recovered GST fusion protein in each sample. The grey vertical bars mark 
amino acids 80-120 and 190-234, the deduced ePABP interaction domains.  The previously characterized Musashi RNA 
recognition motif 1 (RRM1) and 2 (RRM2), as well as GLD2 and PABPC1 interaction domains (GLD2/PABPC1) are 
indicated.  (B) and (C)  Representative experiments from panel A showing ePABP co-association (arrowhead) with the 
indicated Musashi constructs. The position of molecular weight markers are indicated to the left of each panel. 
 
Figure 6: Yeast two hybrid analyses reveal a direct interaction between Musashi1 and the C-terminus of ePABP and 
PABPC1. 
(A)  Schematic representation of the structure of vertebrate PABPs and the specific constructs used for the interaction 
analyses.  (B) Yeast two-hybrid analysis using transcription activator domain fusions with full-length Musashi, or Musashi 
N-terminus (-Nt, amino acids 1-198) or C-terminus (-Ct, amino acids 199-347) with DNA binding domain fusions of X. 
laevis PABP1 and ePABP RRMs 1-2 or an RNA-binding defective version of PABPC1 RRMs 1-2.  (C) Yeast two-hybrid 
analysis using DNA binding domain fusions of PABP1 and ePABP C-terminal regions (-Ct) and the indicated Musashi 
transcription activator domain fusion constructs. IRP-1 and eIF4G N-terminus (4GNt) represent negative and positive 
controls. The relative strength of tested interactions (assessed by colony growth and LexA-dependent b-galactosidase 
expression) are represented by “+” symbols.  The data in B and C are derived from three independent experiments. 
 
Figure 7: Differential association with ePABP correlates with functional differences between Musashi1 and 
Musashi2. 
(A) A representative GST pull-down experiment to assess association between either GST-tagged Xenopus Musashi1 or 
Musashi-2 and endogenous ePABP.  Musashi-2 is severely compromised for ePABP binding.  Uninjected oocytes (UI) or 
oocytes injected with RNA encoding the GST moiety alone serve as specificity controls.  The position of molecular weight 
markers are indicated to the left of each panel. (B) Graphically summary of three independent experiments assessing 
association between Musashi1or Musashi2 and ePABP. Association data is normalized to the levels of recovered GST-
fusion protein in each sample.  Musashi2 is severely compromised for ePABP binding.  ** indicates p<0.01.  (C) Oocytes 
were injected with antisense oligonucleotides targeting Musashi1 and Musashi2.  Following overnight incubation, 
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progesterone-stimulated maturation was measured after injection with mRNA encoding either Xenopus Musashi1 (XMsi1), 
Musashi2 (XMsi2), a chimeric Musashi2 protein that has the Musashi1 ePABP-binding domain substituted for the Musashi2 
ePABP binding domain (Chimera) or water injected control (No rescue).  A summary of three independent experiments is 
shown graphically.  While Musashi2 is rate compromised for mediating oocyte maturation relative to similar levels of 
Musashi1, the chimeric Musahsi2 protein functions as efficiently as Musashi1. * indicates p<0.05; ** indicates p<0.01.  (D) 
The relative protein expression levels of the injected rescue constructs are shown for a representative experiment from panel 
(C).  The position of molecular weight markers are indicated to the left of each panel. 
 
Figure 8:  PABPC1 can functionally compensate for loss of ePABP during oocyte maturation. 
(A) Oocytes were co-injected with mRNA encoding GST-tagged Xenopus PABPC1 and GFP-tagged Xenopus Musashi1 
(GFP-XMsi1), Xenopus Musashi2 (GFP-XMsi2) or the GFP moiety alone. Following overnight incubation, the oocytes 
were lysed, subjected to GST pulldown and PABPC1 co-association assessed by GFP western blotting. A strong interaction 
with Musashi1 is seen (arrowhead), but a greatly reduced interaction with Musashi2 is evident even after correction for 
recovered GST-PABPC1 in the samples.  PABPC1 did not interact with the GFP moiety alone.  (B)  The ability of Musashi1 
or Musashi2 to interact with PABPC1 (Panel F) was assessed in three independent experiments and the data summarized 
graphically.  Association data was normalized to the levels of recovered GST-PABPC1 in each sample.  * indicates p<0.05; 
** indicates p<0.01.  (C)  Oocytes were injected with antisense oligonucleotides targeting ePABP.  Following overnight 
incubation, the oocytes were reinjected with either water ((No rescue) or PABPC1 mRNA (PABPC1 rescue), then 
stimulated with progesterone and the extent maturation was scored (% GVBD). The graph shows the combined data from 
six independent experiments. ****, p<0.0001.   
 
Figure 9:  PABPC1 is associated with Musashi in mammalian cells under conditions of target mRNA translation. 
(A) A representative western blot showing rabbit IgG (Con) or Musashi1 immunoprecipitation using two different 
antibodies (Msi1, Abcam 52865; Msi2, Abcam 114107) from lysate of proliferating SH-SY5Y cells.  Recovery of Musashi1 
and co-associated PABPC1 is shown along with levels of the proteins in starting lysate (1/10th volume of that used for 
immunoprecipitation).  The position of molecular weight markers are indicated to the left of each panel. (B) Activating 
phosphorylation of Musashi1 (p-Msi1) is observed in the lysate of differentiated (Diff) but not proliferating (Pro) SH-SY5Y 
cells.  (C) The composite results of three independent experiments reveals that PABPC1 is present in immnoprecipitated 
Musashi1 protein complexes from both proliferating and differentiated SH-SY5Y cells.  No statistically significant 
difference in Musashi1:PABPC1 co-association was observed between proliferating and differentiated SH-SY5Y cells. (D)  
A representative western blot showing rabbit IgG (Con) or Musashi1 immunoprecipitation using Msi2 (Abcam 114107) 
antibodies from lysate of proliferating hiPSCs (PSC) or differentiated (Diff) hiPSCs.  Recovery of Musashi1 and co-
associated PABPC1 is shown along with levels of the proteins in their respective starting lysate (1/10th volume of that used 
for immunoprecipitation).  (E) Activating phosphorylation of Musashi1 (p-Msi1) is significantly increased in the lysate of 
differentiated (Diff) rather than proliferating hiPSCs.  (F) Composite results of three independent experiments reveals 
PABPC1 is present in immnoprecipitated Musashi1 complexes from both proliferating and from differentiated hiPSCs.  No 
statistically significant difference in Musashi1:PABPC1 co-association was observed between proliferating and 
differentiated hiPSCs.   
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